15 Analysts Assess Axsome Therapeutics: What You Need To Know
Throughout the last three months, 15 analysts have evaluated Axsome Therapeutics (NASDAQ:AXSM), offering a diverse set of opinions…
Hello Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday. Shares…
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics…
Analyst Ratings For Axsome Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Axsome Therapeutics…
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell
• Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Earnings Outlook For Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Tuesday, 2024-02-20. Here’s what investors…
UBS Bullish On This Depression Drug Maker, Says Alzheimer’s Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
The Latest Analyst Ratings For Axsome Therapeutics
In the last three months, 8 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM), offering a diverse range…
Cramer Praises Asset Manager’s ‘Amazing Quarter,’ But As For SolarEdge? ‘Too Hard To Own’
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).